TriLink BioTechnologies社 mRNA医薬の歴史および将来の展望について

In celebration of mRNA Day 2020, TriLink proudly presents back-to-back webinars by two pioneers of the mRNA therapeutic platform: Dr. Katalin Karikó (BioNTech) and Dr. Drew Weissman (University
of Pennsylvania). Dr. Karikó provides an overview of the history of mRNA therapeutics, while Dr. Weissman offers his perspective on the future of mRNA medicines. A moderated Q&A session follows the presentations.

EXPLORE THE VIDEOS

The Future of mRNA Therapeutics is Here

CleanCap mRNA cap analogs are the solution for mRNA researchers seeking manufacturing acceleration, scale-up, and performance. CleanCap co-transcriptional capping technology enables a streamlined one-pot synthesis that generates 3X higher
yield of capped mRNA than ARCA, reducing the overall production timeline and
number of manufacturing steps. Further, CleanCap generates a natural Cap 1
structure that results in better mRNA performance in vivo than Cap 0. Learn more about CleanCap here.

TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO helping life science leaders and innovators overcome challenges in the synthesis and scale-up of nucleic acids, NTPs and mRNA capping analogs with scale-up expertise and unique mRNA production capabilities, including its proprietary
CleanCap^® mRNA capping technology. TriLink continues to expand its cGMP and general mRNA, oligonucleotide & plasmid manufacturing capacity at its new global headquarters to support therapeutic, vaccine and diagnostic customers.

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。